Articles From: Immune Pharmaceuticals Appoints Gad Berdugo as Chief Financial Officer and Dr. Cameron Durrant as Lead Independent Director to Immunomedics Reports Expanded Phase 1/2 Trials Confirm Activity and Good Safety Profile of Sacituzumab Govitecan (Immu-132) in Patients With Advanced Triple-Negative Breast Cancer


2015/1/21
NEW YORK and HERZLIYA PITUACH, Israel , Jan.
Sign-up for Immune Pharmaceuticals Appoints Gad Berdugo as Chief Financial Officer and Dr. Cameron Durrant as Lead Independent Director investment picks
2015/2/9
NEW YORK , Feb.
Sign-up for Immune Pharmaceuticals Appoints Paul Nadler, MD, EVP, R&D and Chief Medical Officer investment picks
2014/12/15
NEW YORK and HERZLIYA PITUACH, Israel , Dec.
Sign-up for Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. investment picks
2015/2/5
NEW YORK , Feb.
Sign-up for Immune Pharmaceuticals To Present At The BIO CEO & Investor Conference investment picks
2014/12/17
LOS ANGELES , Dec.
Sign-up for ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine investment picks
2015/1/28
LOS ANGELES , Jan.
Sign-up for ImmunoCellular Therapeutics to Present at the BIO CEO & Investor Conference on February 9, 2015 investment picks
2015/2/12
LOS ANGELES , Feb.
Sign-up for ImmunoCellular Therapeutics, Ltd. Announces Pricing of a Public Offering of Common Stock and Warrants investment picks
2014/12/19
ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today reported that Roche has announced top-line results of its Phase III MARIANNE study.
Sign-up for ImmunoGen Reports Roche Has Provided an Update on the MARIANNE Trial investment picks
2015/1/11
ImmunoGen, Inc .
Sign-up for ImmunoGen, Inc. Announces 2015 Outlook for Product Pipeline investment picks
2015/1/21
ImmunoGen, Inc .
Sign-up for ImmunoGen, Inc. Announces Conference Call to Discuss its Second Quarter Fiscal Year 2015 Financial Results investment picks
2014/12/15
ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that Daniel Junius, President and CEO, will present at the upcoming 33 rd Annual J.P. Morgan Healthcare Conference in San Francisco.
Sign-up for ImmunoGen, Inc. Announces Webcast of Presentation at the 33rd Annual J.P. Morgan Healthcare Conference investment picks
2015/2/24
ImmunoGen, Inc .
Sign-up for ImmunoGen, Inc. Announces Webcast of Presentation at Upcoming Investor Conference investment picks
2015/2/4
ImmunoGen, Inc .
Sign-up for ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences investment picks
2015/1/30
ImmunoGen, Inc .
Sign-up for ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2015 Financial Results investment picks
2014/12/19
ImmunoGen's stock (IMGN) plunged to a more than four-year low in very-active trade Friday afternoon, after Leerink Partners downgraded it to market perform from outperform, following disappointing trial results for Roche Holding's (RHHBY) . Leerink analyst Michael Schmidt also cut his stock price target to $7 from $15. Roche's drug Kadcyla utilizes ImmunoGen's antibody-drug conjugate technology.
Sign-up for ImmunoGen's stock plunges after Roche's disappointing trial results prompts downgrade investment picks
2015/2/12
MORRIS PLAINS, N.J., Feb.
Sign-up for Immunomedics Announces Completion of Offering of $85 Million of 4.75% Convertible Senior Notes Due 2020 investment picks
2015/2/3
MORRIS PLAINS, N.J., Feb.
Sign-up for Immunomedics Announces Conference Call and Webcast for Second Quarter Fiscal 2015 Financial Results investment picks
2015/1/29
MORRIS PLAINS, N.J., Jan.
Sign-up for Immunomedics Announces Dismissal of Putative Class Action Lawsuit investment picks
2014/12/3
MORRIS PLAINS, N.J., Dec.
Sign-up for Immunomedics Announces Outcome of 2014 Annual Meeting of Stockholders investment picks
2015/2/5
MORRIS PLAINS, N.J., Feb.
Sign-up for Immunomedics Announces Pricing of Offering of $85 Million of 4.75% Convertible Senior Notes Due 2020 investment picks
2015/2/4
MORRIS PLAINS, N.J., Feb.
Sign-up for Immunomedics Announces Proposed Offering of $85 Million of Convertible Senior Notes Due 2020 investment picks
2015/2/4
MORRIS PLAINS, N.J., Feb.
Sign-up for Immunomedics Announces Second Quarter Fiscal 2015 Results and Clinical Program Developments investment picks
2015/1/6
MORRIS PLAINS, N.J., Jan.
Sign-up for Immunomedics Appoints Dr. Francois Wilhelm Chief Medical Officer investment picks
2015/1/5
MORRIS PLAINS, N.J., Jan.
Sign-up for Immunomedics Awarded Fast Track Designation by FDA for Sacituzumab Govitecan (IMMU-132) for Triple-Negative Breast Cancer Therapy investment picks
2015/2/19
SANTA MONICA, Calif., Feb.
Sign-up for Immunomedics Presents Updated Results With Sacituzumab Govitecan in Lung Cancer investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Immune Pharmaceuticals Appoints Gad Berdugo as Chief Financial Officer and Dr. Cameron Durrant as Lead Independent Director to Immunomedics Reports Expanded Phase 1/2 Trials Confirm Activity and Good Safety Profile of Sacituzumab Govitecan (Immu-132) in Patients With Advanced Triple-Negative Breast Cancer
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent